Article Information
History
- October 24, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Jay Noboru Worley1,2,
- Nicholas D. Benedetto1,
- Mary Delaney1,3,
- Ana Oliveira Paiva4,
- Marie-Pierre Chapot-Chartier5,
- Johann Peltier4 and
- Lynn Bry1,3,*
- 1Massachusetts Host-Microbiome Center, Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 2National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland, USA
- 3Clinical Microbiology Laboratory, Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 4Institute for Integrative Biology of the Cell, University of Paris-Saclay, Alternative Energies and Atomic Energy Commission, National Centre for Scientific Research, Gif-sur-Yvette, France
- 5AgroParisTech, Micalis Institute, University of Paris-Saclay, National Research Institute for Agriculture, Food and Environment, Jouy-en-Josas, Franc
- ↵*Corresponding author; email: lbry{at}bwh.harvard.edu
Posted October 24, 2023.
Clostridioides difficile MreE (PBP2) variants facilitate clinical disease during cephalosporin exposures
